Skip to content

US · SPRO · BIOTECHNOLOGY

Spero Therapeutics, Inc. (SPRO) intrinsic value and stock valuation

$0.74as of 2026-11-21 · Mkt cap 72.96M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Spero Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values SPRO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SPRO’s statements →

Spero Therapeutics, Inc. Graham Number

Graham Number: $1.90d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02139 sperotherapeutics.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$59.6M+44.9% 5y CAGRd
20152025
Net income
$8.57M
20152025
Free cash flow
-$-12.62M
20152025
Total equity
$59M-14.9% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$59.6M$48M$103.8M$48.6M$3.07M
Operating income-$-20K-$-73.36M$21.5M-$-42.2M-$-87.97M
Net income$8.57M-$-68.57M$22.8M-$-46.41M-$-89.76M
EPSd$145.2K-$-1.27M$430.5K-$-1.23M-$-2.9M
Operating cash flow-$-12.62M-$-23.44M-$-32.99M-$-7.73M-$-64.35M
Capital expenditure$0.00$0.00$0.00$0.00$64.4M
Free cash flow-$-12.62M-$-23.44M-$-32.99M-$-7.73M-$-64.35M
Total assets$68.9M$110.5M$182.4M$124.8M$171.1M
Total debt$2.9M$4.3M$5.54M$6.65M$7.33M
Net debt-$-37.37M-$-48.59M-$-70.79M-$-102.46M-$-105.25M
Total equity$59M$46.1M$106.9M$75.9M$88.3M
Cash and short-term investments$40.3M$52.9M$76.3M$109.1M$146.4M
Income statement
20252024202320222021
Revenue$59.6M$48M$103.8M$48.6M$3.07M
Cost of revenue$0.00$96.8M$51.4M$0.00$0.00
Gross profit$59.6M-$-48.78M$52.3M$48.6M$3.07M
Research and development expenses$38.5M$96.8M$51.4M$47.6M$64.5M
Selling, general and administrative expenses$21.2M$23.7M$25.6M$36.5M$41.7M
Other expenses$0.00-$-95.88M-$-46.13M$6.7M-$-15.19M
Operating expenses$59.6M$24.6M$30.9M$90.8M$91M
Cost and expenses$59.6M$121.3M$82.3M$90.8M$91M
Interest income$2.51M$4.74M$3.94M$1.11M$350K
Interest expense$0.00$0.00$0.00$2.6M$1.94M
Depreciation and amortization$0.00$0.00$370K$870K$650K
Ebitda$8.83M-$-72.48M$27.2M-$-42.94M-$-87.17M
Operating income-$-20K-$-73.36M$21.5M-$-42.2M-$-87.97M
Total other income/expenses, net$8.86M$4.79M$3.92M-$-4.22M-$-1.78M
Income before tax$8.83M-$-68.57M$25.4M-$-46.41M-$-89.76M
Income tax expense$260K$0.00$2.6M$0.00$0.00
Net income$8.57M-$-68.57M$22.8M-$-46.41M-$-89.76M
Weighted average shares outstanding$56M$54M$52.7M$37.6M$30.9M
Weighted average diluted shares outstanding$59M$54M$53M$37.6M$30.9M
Balance sheet
20252024202320222021
Cash and short-term investments$40.3M$52.9M$76.3M$109.1M$146.4M
Net receivables$25.4M$52.5M$50.7M$1.08M$2.64M
Inventory$0.00$0.00$0.00-$-4.46M$0.00
Total current assets$67.3M$107.3M$131.2M$109.1M$157.9M
Property, plant and equipment, net$1.48M$3.11M$4.16M$5.49M$7.56M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$46.6M$0.00$0.00
Total non-current assets$1.63M$3.27M$51.2M$15.7M$13.2M
Total assets$68.9M$110.5M$182.4M$124.8M$171.1M
Accounts payable$690K$7.31M$1.38M$620K$1.1M
Short-term debt$1.96M$1.75M$1.72M$1.69M$1.36M
Deferred revenue$260K$22.1M$27.1M$10.4M$1.86M
Total current liabilities$8.87M$49.1M$37.2M$21.7M$18.7M
Long-term debt$940K$2.55M$3.83M$4.96M$5.97M
Deferred revenue, non-current$0.00$12.2M$34.4M$22.2M$8.79M
Total non-current liabilities$1.03M$15.4M$38.3M$27.2M$64.1M
Capital lease obligations$940K$2.55M$3.83M$4.96M$7.33M
Total liabilities$9.9M$64.4M$75.5M$48.9M$82.8M
Common stock$60K$60K$50K$50K$30K
Retained earnings-$-451.07M-$-459.64M-$-391.07M-$-413.88M-$-367.46M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$0.00
Total equity$59M$46.1M$106.9M$75.9M$88.3M
Total investments$0.00$0.00$46.6M$0.00$33.8M
Total debt$2.9M$4.3M$5.54M$6.65M$7.33M
Net debt-$-37.37M-$-48.59M-$-70.79M-$-102.46M-$-105.25M
Cash flow statement
20252024202320222021
Net income$8.57M-$-68.57M$22.8M-$-46.41M-$-89.76M
Depreciation and amortization$0.00$0.00$370K$870K$1.12M
Stock-based compensation$4.33M$7.79M$7.93M$9.12M$9.43M
Change in working capital-$-27.16M$36.3M-$-70.38M$22.1M$12.9M
Accounts receivable$3.06M-$-1.54M-$-460K$1.55M$3.83M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-6.61M$5.93M$760K-$-480K-$-50K
Net cash provided by operating activities-$-12.62M-$-23.44M-$-32.99M-$-7.73M-$-64.35M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$40K
Net cash used for investing activities$0.00$0.00$0.00$33.8M$7.67M
Common stock issued$0.00$0.00$220K$24.9M$36.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$0.00$0.00$220K-$-29.55M$84.1M
Net change in cash-$-12.62M-$-23.44M-$-32.77M-$-3.48M$27.4M
Cash at end of period$40.3M$52.9M$76.3M$109.1M$112.6M
Operating cash flow-$-12.62M-$-23.44M-$-32.99M-$-7.73M-$-64.35M
Capital expenditure$0.00$0.00$0.00$0.00$64.4M
Free cash flow-$-12.62M-$-23.44M-$-32.99M-$-7.73M-$-64.35M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Spero Therapeutics, Inc.

        Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

        CEO
        Esther Rajavelu
        Employees
        25
        Beta
        1.49

        Explore

        Frequently asked questions

        What is the intrinsic value of Spero Therapeutics, Inc. (SPRO)?

        InvestorsCraft does not currently publish an intrinsic value for SPRO. How the IC value is calculated.

        Is SPRO undervalued?

        InvestorsCraft does not publish an undervaluation signal for SPRO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.